Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

Men, baby boomers, and postgraduate-degree holders were among those most likely to say they wouldn’t choose medication over ...

A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...

Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, from its ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Federal regulators shook up a rapidly growing pharmaceutical marketplace when they announced that tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, was no longer in shortage ...